Allena Pharmaceuticals, Inc. Operating CF/Net income

Operating CF/Net income of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating CF/Net income growth rates and interactive chart. Calculated as operating cash flow divided by net income to common shareholders. Also called income quality ratio. A ratio of greater than 1.0 usually indicates high-quality income, while a ratio of less than 1.0 indicates low-quality.


Highlights and Quick Summary

  • Operating CF/Net income for the quarter ending March 31, 2022 was 1.7 (a 38.1% increase compared to previous quarter)
  • Year-over-year quarterly Operating CF/Net income increased by 109.98%
  • Annual Operating CF/Net income for 2021 was 0.93 (a 10.99% increase from previous year)
  • Annual Operating CF/Net income for 2020 was 0.84 (a -7.72% decrease from previous year)
  • Annual Operating CF/Net income for 2019 was 0.91 (a 1.95% increase from previous year)
  • Twelve month Operating CF/Net income ending March 31, 2022 was 1.14 (a 21.76% increase compared to previous quarter)
  • Twelve month trailing Operating CF/Net income increased by 46.92% year-over-year
Trailing Operating CF/Net income for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
1.14 0.93 0.83 0.77
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating CF/Net income of Allena Pharmaceuticals, Inc.

Most recent Operating CF/Net incomeof ALNA including historical data for past 10 years.

Interactive Chart of Operating CF/Net income of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Operating CF/Net income for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 1.7
2021 1.23 0.9 0.81 0.86 0.93
2020 0.74 0.63 0.96 1.13 0.84
2019 1.05 0.68 1.14 0.86 0.91
2018 0.91 0.86 0.93 0.88 0.89
2017 1.02 0.75 0.95 1.11 0.97
2016 0.0 2.87 0.95
2015 0.0 0.92

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.